What are the current adult treatment guidelines for asthma, chronic obstructive pulmonary disease, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, obstructive sleep apnea, and acute COVID‑19?

Current Adult Treatment Guidelines for Pulmonology Conditions

Asthma

For adults with mild persistent asthma (step 2), either daily low-dose inhaled corticosteroids (ICS) plus as-needed short-acting β2-agonists (SABA) OR as-needed concomitant ICS and SABA therapy are recommended 1.

Treatment Algorithm by Severity:

Step 1 (Intermittent Asthma):

• As-needed SABA for rescue therapy only 1

Step 2 (Mild Persistent):

• Daily low-dose ICS + as-needed SABA, OR
• As-needed concomitant ICS and SABA 1

Step 3 (Moderate Persistent):

• ICS-formoterol combination (single maintenance and reliever therapy) is the preferred therapy - use low-dose ICS-formoterol for both daily maintenance and as-needed rescue 1

Step 4 (Moderate-Severe Persistent):

• Medium-dose ICS-formoterol for both daily and as-needed therapy 1

Step 5 (Severe Persistent):

• Add long-acting muscarinic antagonists (LAMA) to ICS-formoterol therapy 1

Key Management Points:

• Do NOT recommend short-term increases in ICS dose alone for worsening symptoms 1
• Fractional exhaled nitric oxide (FeNO) testing assists in diagnosis and monitoring but should not be used alone 1
• Indoor allergen mitigation only when specific exposure and sensitivity documented; must be allergen-specific with multiple strategies 1
• Subcutaneous immunotherapy recommended as adjunct when symptoms and sensitization present 1
• Bronchial thermoplasty NOT recommended as standard care 1

---

Chronic Obstructive Pulmonary Disease (COPD)

All symptomatic COPD patients should receive long-acting inhaled bronchodilator maintenance therapy plus as-needed SABD therapy, regardless of disease severity 2.

Treatment by Risk Stratification:

Mild Disease (Symptomatic):

• Trial of inhaled β2-agonist OR anticholinergic as needed 3
• If ineffective, discontinue 3

Moderate Disease:

• Single inhaled LAMA/LABA dual therapy (superior to monotherapy) 2
• Regular therapy with either drug or combination may be needed 3
• Consider corticosteroid trial in all patients 3

Severe Disease:

• Combination β2-agonist and anticholinergic bronchodilators 3
• Consider theophyllines (monitor for side effects) 3
• Assess for home nebulizer using BTS guidelines 3

High Risk of Exacerbations (≥2 moderate OR ≥1 severe exacerbation in past year):

• LAMA/LABA/ICS triple combination therapy in a single inhaler (SITT) is strongly recommended 2
• This reduces mortality, dyspnea, improves health status and lung function, and prevents moderate-to-severe exacerbations 2
• Specifically for patients with high symptom burden (mMRC ≥2, CAT ≥10) and FEV1 <80% predicted 2

Acute Exacerbations Management:

Criteria for Antibiotic Use (need 2 of 3):

1. Increased breathlessness
2. Increased sputum volume
3. Development of purulent sputum 3

Oral Corticosteroids (30 mg/day for 1 week) only if:

• Already on oral corticosteroids
• Previously documented response
• Airflow obstruction fails to respond to increased bronchodilator dose
• First presentation of airflow obstruction 3

Non-Pharmacological:

• Smoking cessation is essential at all stages - prevents accelerated decline but cannot restore lost function 3
• Pulmonary rehabilitation improves exercise performance and reduces breathlessness in moderate/severe disease 3
• Long-term oxygen therapy (LTOT) prolongs life when PaO2 <7.3 kPa 3
• Influenza vaccination recommended, especially for moderate-to-severe disease 3

Critical Pitfall:

Do NOT use inhaled corticosteroids alone to prevent LRTI - they may actually increase pneumonia risk in COPD patients 4. Use only as part of triple therapy in high-risk exacerbators.

---

Idiopathic Pulmonary Fibrosis (IPF)

The majority of IPF patients should receive pulmonary rehabilitation, which improves walk distance, symptoms, and quality of life 5.

Pharmacological Treatment:

Antifibrotic Therapy:

• Nintedanib and pirfenidone are the recommended pharmacological therapies 6
• Should be initiated at diagnosis in appropriate candidates 6

Acute Exacerbation Management:

The majority of patients with acute exacerbation of IPF should be treated with corticosteroids (weak recommendation due to lack of controlled trials) 5.

• Intravenous corticosteroids up to 1 gram per day have been reported 5
• Supportive care is the mainstay of therapy 5

Pulmonary Hypertension in IPF:

• Limited data on treatment effectiveness 5
• Pulmonary-artery-specific therapies may worsen clinical status 5
• Single-dose sildenafil improved hemodynamics without worsening oxygenation 5

Rehabilitation and Recovery:

Pulmonary rehabilitation should include:

• Combined exercise (aerobic with strength)
• Specific respiratory exercises
• Respiratory muscle training 7

For pulmonary fibrosis recovery:

• Posture management
• Breathing exercise management
• Traditional exercises (Baduanjin, Tai-chi, 6-character breathing) 7

Monitoring for Progressive Pulmonary Fibrosis (PPF):

PPF defined as ≥2 of the following within past year:

1. Worsening respiratory symptoms
2. FVC decline >5% predicted OR DLCO decline >10% predicted
3. Radiological progression (increased traction bronchiectasis, new ground-glass opacity, new/increased reticulation or honeycombing) 6

• Evaluate pulmonary function every 4-6 months 6
• Annual HRCT if clinical suspicion of worsening or lung cancer risk 6
• Evaluate for lung transplantation at diagnosis if increased mortality risk 6

---

Pulmonary Arterial Hypertension

The provided evidence does not contain specific treatment guidelines for primary pulmonary arterial hypertension. However, for pulmonary hypertension associated with lung diseases (WHO Group 3):

• Positive airway pressure therapy for OSA shows promise in obesity hypoventilation syndrome and COPD 8
• Pulmonary-artery-specific therapies carry risk of clinical worsening in Group 3 PH 8
• Weight management has emerged as crucial intervention 8

---

Obstructive Sleep Apnea (OSA)

Treatment is recommended in all patients with OSA who have symptoms OR systemic hypertension 9.

Treatment Indications:

Definite Treatment:

• All symptomatic OSA patients
• OSA with systemic hypertension 9

Consider Treatment in Asymptomatic Patients with:

• Moderate-to-severe OSA AND COPD with pulmonary hypertension
• Comorbid cardiovascular disease
• Comorbid cerebrovascular disease
• Marked hypoxic burden 9

Treatment Modalities:

CPAP:

• Effective first-line therapy 9

High-Intensity Noninvasive Ventilation (NIV):

• In overlap syndrome (OSA + COPD) with daytime hypercapnia, high-intensity NIV aiming to lower PaCO2 may have additional benefits over CPAP 9

Supplemental Oxygen:

• In patients with severe resting daytime hypoxemia, supplemental oxygen improves survival and should be added to positive airway pressure 9

OSA in Comorbid Conditions:

• OSA is common in IPF patients but specific treatment recommendations are limited 5
• In COPD-OSA overlap, identifying symptoms attributable to OSA can be challenging 9

---

Acute COVID-19

For severe COVID-19, rehabilitation care should be implemented as soon as possible in parallel with disease treatment 7.

Acute Phase Management:

Rehabilitation Interventions:

• Passive and active activities when oxygenation and hemodynamics stable 7
• Promotes sputum drainage and pulmonary rehabilitation 7
• Timing decided by multidisciplinary team based on medical condition 7

Convalescent Phase (Post-Severe COVID-19):

For potential pulmonary fibrosis:

• Pulmonary rehabilitation training including combined exercise (aerobic with strength), respiratory exercises, and respiratory muscle training 7
• Traditional Chinese medicine approaches with syndrome differentiation (weak recommendation) 7
• Baduanjin, Tai-chi, 6-character breathing exercise, posture management, breathing exercises (strong recommendation) 7

COPD Management During COVID-19:

Continue basic COPD treatment with strict adherence to dosing - this may protect against post-inflammatory pulmonary fibrosis 10.

Key Modifications:

• Good disease management with inhaled preparations including ICS 10
• Monitor concomitant infections 10
• Use vaccinations to reduce COVID-19 risk 10
• Limit spirometric testing to reduce SARS-CoV-2 transmission risk 10

Important Caveat:

The evidence for COVID-19 treatment is evolving. The 2021 guideline 7 represents early pandemic recommendations. Current practice should incorporate the most recent national and international guidance, as treatment protocols have evolved significantly since 2021.